Servier drops GeNeuro’s multiple sclerosis drug after midphase miss

Servier has turned down the chance to license a multiple sclerosis drug from GeNeuro. The decision comes a year after the monoclonal antibody, GNbAC1, failed to beat placebo in a phase 2b trial.